Trial · NCT02596126
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Major Cardiovascular Adverse Events (MACE) | Treatment Prevention for Secondary CV | 156 | number of adjudicated events | ||
| Major Cardiovascular Adverse Events (MACE) | Cardiovascular Polypill | 118 | number of adjudicated events | ||
| Efficacy Endpoints | Treatment Prevention for Secondary CV | Low adherence (0-5) | 9.5 | percentage of participants | |
| Efficacy Endpoints | Cardiovascular Polypill | Low adherence (0-5) | 5.5 | percentage of participants | |
| Efficacy Endpoints | Treatment Prevention for Secondary CV | Medium adherence (6-7) | 27.8 | percentage of participants | |
| Efficacy Endpoints | Cardiovascular Polypill | Medium adherence (6-7) | 24.0 | percentage of participants | |
| Efficacy Endpoints | Treatment Prevention for Secondary CV | High adherence (8) | 62.7 | percentage of participants | |
| Efficacy Endpoints | Cardiovascular Polypill | High adherence (8) | 70.6 | percentage of participants | |
| Safety Endpoints | Treatment Prevention for Secondary CV | 117 | number of events | ||
| Safety Endpoints | Cardiovascular Polypill | 115 | number of events | ||
| Efficacy Endpoints | Treatment Prevention for Secondary CV | Low adherence (0-5) | 6.9 | percentage of participants | |
| Efficacy Endpoints | Cardiovascular Polypill | Low adherence (0-5) | 4.2 | percentage of participants | |
| Efficacy Endpoints | Treatment Prevention for Secondary CV | Medium adherence (6-7) | 29.8 | percentage of participants | |
| Efficacy Endpoints | Cardiovascular Polypill | Medium adherence (6-7) | 21.7 | percentage of participants | |
| Efficacy Endpoints | Treatment Prevention for Secondary CV | High adherence (8) | 63.2 | percentage of participants | |
| Efficacy Endpoints | Cardiovascular Polypill | High adherence (8) | 74.1 | percentage of participants | |
| Efficacy Endpoints | Treatment Prevention for Secondary CV | 134.8 | Standard Deviation 18.1 | millimeters of mercury (mmHg) | |
| Efficacy Endpoints | Cardiovascular Polypill | 134.4 | Standard Deviation 17.7 | millimeters of mercury (mmHg) | |
| Efficacy Endpoints | Treatment Prevention for Secondary CV | 135.0 | Standard Deviation 18.0 | millimeters of mercury (mmHg) | |
| Efficacy Endpoints | Cardiovascular Polypill | 136.3 | Standard Deviation 17.5 | millimeters of mercury (mmHg) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02596126/results